Text Size

A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy

Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F; VISIONARY Study Group

  • 2022
  • Current Medical Research and Opinion
View publication
  • Therapeutic Area


  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Tutkimusz Ltd., Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Department of Ophthalmology, Instituto Oftalmologico Gomez-Ulla, Santiago de Compostela, Galicia, Spain; Department of Ophthalmology, LLC Vzglyad, Leningradskaya, Chita, Russia; Medical Affairs, Santen SA, Geneva, Switzerland; Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022